Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes

Journal of Biochemical and Molecular Toxicology

Volumn 20, Issue 2, 2006, Pages 69-78

  Graham, Richard A ^a,b   Tyler, Lindsey O ^b   Krol, Wojciech L ^b   Silver, Ivin S ^b   Webster, Lindsey O ^b   Clark, Philip ^b   Chen, Liangfu ^b   Banks, Troy ^b   LeCluyse, Edward L ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CellzDirect   (United States)

Author keywords

Beagle dog; CYP; Hepatocytes; Induction; mRNA expression; Regulation

Indexed keywords

BETA NAPHTHOFLAVONE; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 2B; CYTOCHROME P450 2B11; CYTOCHROME P450 3A; CYTOCHROME P450 3A12; CYTOCHROME P450 3A4; ETHOXYRESORUFIN DEETHYLASE; MESSENGER RNA; PHENOBARBITAL; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME REGULATION; LIVER CELL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RNA ANALYSIS;

ANIMALS; BETA-NAPHTHOFLAVONE; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTES; KINETICS; MALE; PHENOBARBITAL; RIFAMPIN; RNA, MESSENGER; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 33645828842     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20118     Document Type: Article

References (29)

1. Uchida T, Komori M, Kitada M, Kamataki T. Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol Pharmacol 1990;38(5):644-651.
2. Graves PE, Elhag GA, Ciaccio PJ, Bourque DP, Halpert JR. cDNA and deduced amino acid sequences of a dog hepatic cytochrome P450IIB responsible for the metabolism of 2,2′,4,4′,5,5′-hexachlorobiphenyl. Arch Biochem Biophys 1990;281(1):106-115.
3. Blaisdell J, Goldstein JA, Bai SA. Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 1998;26(3):278-283.
4. Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R, Takanaka A, Matsubara T. A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: Purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 1995;319(2):372-382.
5. Lankford SM, Bai SA, Goldstein JA. Cloning of canine cytochrome P450 2E1 cDNA: Identification and characterization of two variant alleles. Drug Metab Dispos 2000;28(8):981-986.
6. Ciaccio PJ, Graves PE, Bourque DP, Glinsmann-Gibson B, Halpert JR. cDNA and deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. Biochim Biophys Acta 1991;1088(2):319-322.
7. Fraser DJ, Feyereisen R, Harlow GR, Halpert JR. Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 1997;283(3):1425-1432.
8. Nishibe Y, Wakabayashi M, Harauchi T, Ohno K. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 1998;28(6):549-557.
9. Graham RA, Downey A, Mudra D, Krueger L, Carroll K, Chengelis C, Madan A, Parkinson A. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos 2002;30(11):1206-1213.
10. Korytko P, Casey A, Bush B, Quimby F. Induction of hepatic cytochromes P450 in dogs exposed to a chronic low dose of polychlorinated biphenyls. Toxicol Sci 1999;47(1):52-61.
11. LeCluyse EL. Pregnane X receptor: Molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 2001;134(3):283-289.
12. Madan A, DeHaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab Dispos 1999;27(3):327-335.
13. LeCluyse EL, Bullock PL, Parkinson A, Hochman JH. Cultured rat hepatocytes. Pharm Biotechnol 1996;8:121-159.
14. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
15. Seglen PO, Gordon PB, Poli A. Amino acid inhibition of the autophagic/lysosomal pathway of protein degradation in isolated rat hepatocytes. Biochim Biophys Acta 1980;630(1):103-118.
16. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150(1):76-85.
17. Burke MD, Mayer RT. Ethoxyresorufin: Direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 1974;2(6):583-588.
18. Klekotka PA, Halpert JR. Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11). Drug Metab Dispos 1995;23(12):1434-1435.
19. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1987;255(1):27-41.
20. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004;32(3):348-358.
21. Foxworthy PS, White SL, Hoover DM, Eacho PI. Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicol Appl Pharmacol 1990;104(3):386-394.
22. LeCluyse E, Bullock P, Madan A, Carroll K, Parkinson A. Influence of extracellular matrix overlay and medium formulation on the induction of cytochrome P-450 2B enzymes in primary cultures of rat hepatocytes. Drug Metab Dispos 1999;27(8):909-915.
23. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68(4):356-366.
24. Adedoyin A, Aarons L, Houston JB. Time-dependent disposition of beta-naphthoflavone in the rat. Pharm Res 1993;10(1):35-43.
25. Smith CM, Faucette SR, Wang H, LeCluyse EL. Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J Biochem Mol Toxicol 2005;19(2):96-108.
26. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31(5):533-539.
27. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004;44(11):1273-1281.
28. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;36(1):164-172.
29. Courtois A, Payen L, Le Ferrec E, Scheffer GL, Trinquart Y, Guillouzo A, Fardel O. Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochromes P450 2B1/2 and 3A1/2 in phenobarbital-treated hepatocytes. Biochem Pharmacol 2002;63(2):333-341.